SEC Form 8-K Summary
Registrant: Jupiter Wellness, Inc. The provided request metadata identifies BONK, INC., but the filing names Jupiter Wellness, Inc. as the registrant.
Reporting date: May 4, 2022. The filing was submitted under Item 7.01, Regulation FD Disclosure.
Business Context
The company announced that it will present its JW-300 product at an upcoming conference. The filing incorporates the related May 4, 2022 press release as Exhibit 99.1, but the supplied filing text does not identify the conference date, location, presentation details, or product-development milestones.
Financial Metrics and Capitalization
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, operating results, or other financial metrics. No financial statements were included in the supplied text.
The company’s common stock trades under the symbol JUPW and its warrants under JUPWW on the Nasdaq Capital Market. The warrants are exercisable for one share of common stock at $8.50 per share.
Material Changes Versus Prior Period
The filing does not report a change in financial performance, capital structure, indebtedness, liquidity, or operations versus a prior comparable period. The disclosed event is the planned presentation of JW-300.
Guidance, Outlook, Risks, and Unusual Items
The filing contains customary forward-looking-statement disclaimers. It states that actual results may differ materially because of risks and uncertainties and that the company does not undertake to update forward-looking statements except as required by law.
No specific financial guidance, commercial targets, contingencies, legal proceedings, or unusual accounting items are disclosed in the supplied text.
Investor Verification Items
- Verify the registrant identity because the request metadata and filing identify different companies.
- Review Exhibit 99.1 for the conference details, JW-300 claims, timing, and any additional forward-looking statements.
- Confirm whether the planned presentation resulted in commercial, regulatory, or partnership developments.
- Review subsequent filings for financial results, financing activity, liquidity, debt, and developments related to JW-300.
- Confirm the terms and potential dilution associated with the JUPWW warrants.